Drug Profile
Octreotide oral formulation - Arisgen
Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Arisgen
- Class Antineoplastics; Cyclic peptides; Indoles; Somatostatins
- Mechanism of Action Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Cancer in Switzerland (PO)
- 28 Jan 2019 No recent reports of development identified for preclinical development in Cancer in Switzerland (PO)